Targeted delivery of Protein Arginine Deiminase-4 inhibitors to limit arterial intimal NETosis and preserve endothelial integrity.
暂无分享,去创建一个
P. Libby | O. Farokhzad | Colette Bichsel | K. Croce | Jinjun Shi | R. Molinaro | G. Sukhova | C. Corbo | E. Shvartz | M. Yu | G. Lee | E. Folco | Grasiele Sausen | Y. Tesmenitsky | Yuan Liu | F. Kloss | Yevgenia Tesmenitsky
[1] P. Libby,et al. Roles of PAD4 and NETosis in Experimental Atherosclerosis and Arterial Injury: Implications for Superficial Erosion , 2018, Circulation research.
[2] G. Pruijn,et al. NETosis, complement, and coagulation: a triangular relationship , 2018, Cellular & Molecular Immunology.
[3] J. Ärnlöv,et al. Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice , 2017, Oncoimmunology.
[4] O. Farokhzad,et al. Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr−/− Mice , 2017, Advanced healthcare materials.
[5] Jonathan Rasmussen,et al. Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy. , 2017, Nano letters.
[6] P. Libby,et al. Flow Perturbation Mediates Neutrophil Recruitment and Potentiates Endothelial Injury via TLR2 in MiceNovelty and Significance , 2017 .
[7] Hang Lee,et al. Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study) , 2016, European heart journal.
[8] Gerard Pasterkamp,et al. Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease , 2017, Nature Reviews Cardiology.
[9] Omid C Farokhzad,et al. Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy. , 2016, Angewandte Chemie.
[10] Suresh Gadde,et al. Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis. , 2016, ACS nano.
[11] P. Libby,et al. Redundancy of IL-1 Isoform Signaling and Its Implications for Arterial Remodeling , 2016, PloS one.
[12] P. Libby,et al. Requiem for the 'vulnerable plaque'. , 2015, European heart journal.
[13] O. Guenat,et al. Primary Human Lung Pericytes Support and Stabilize In Vitro Perfusable Microvessels. , 2015, Tissue engineering. Part A.
[14] O. Farokhzad,et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice , 2015, Science Translational Medicine.
[15] David M. Wilson,et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation , 2015, Nature chemical biology.
[16] O. Farokhzad,et al. A Solvent-Free Thermosponge Nanoparticle Platform for Efficient Delivery of Labile Proteins , 2014, Nano letters.
[17] P. Kubes,et al. NETosis: how vital is it? , 2013, Blood.
[18] Robert Langer,et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles , 2013, Proceedings of the National Academy of Sciences.
[19] P. Thompson,et al. Activation of PAD4 in NET formation , 2012, Front. Immun..
[20] Akiko Maehara,et al. A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.
[21] Robert Langer,et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature , 2010, Proceedings of the National Academy of Sciences.
[22] O. Tricot,et al. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. , 2000, Circulation.
[23] P. Libby,et al. Inflammatory Cytokines and Oxidized Low Density Lipoproteins Increase Endothelial Cell Expression of Membrane Type 1-Matrix Metalloproteinase* , 1999, The Journal of Biological Chemistry.
[24] P. Libby,et al. Inducible interleukin-1 gene expression in human vascular smooth muscle cells. , 1986, The Journal of clinical investigation.